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ABSTRACT
Plasticizers with estrogenic activity, such as bisphenol A (BPA), have potential adverse health effects in humans. Due to
mounting evidence of these health effects, BPA is being phased out and replaced by other bisphenol variants in “BPA-free”
products. We have compared estrogenic activity of BPA with 6 bisphenol analogues [bisphenol S (BPS); bisphenol F (BPF);
bisphenol AP (BPAP); bisphenol AF (BPAF); bisphenol Z (BPZ); bisphenol B (BPB)] in 3 human breast cancer cell lines.
Estrogenicity was assessed (1011–104 M) by cell growth in an estrogen receptor (ER)-mediated cell proliferation assay, and
by the induction of estrogen response element-mediated transcription in a luciferase assay. BPAF was the most potent
bisphenol, followed by BPB>BPZ  BPA>BPF  BPAP>BPS. The addition of ICI 182,780 antagonized the activation of ERs.
Data mining of ToxCast high-throughput screening assays confirm our results but also show divergence in the sensitivities
of the assays. Gene expression profiles were determined in MCF-7 cells by microarray analysis. The comparison of
transcriptome profile alterations resulting from BPA alternatives with an ERa gene expression biomarker further indicates
that all BPA alternatives act as ERa agonists in MCF-7 cells. These results were confirmed by Illumina-based RNA
sequencing. In conclusion, BPA alternatives are not necessarily less estrogenic than BPA in human breast cancer cells.
BPAF, BPB, and BPZ were more estrogenic than BPA. These findings point to the importance of better understanding the risk
of adverse effects from exposure to BPA alternatives, including hormone-dependent breast cancer.
Key words: bisphenol; toxicogenomics; endocrine; estrogens; cell culture.
Plasticizers such as bisphenol A (BPA) have been reported to
have potential adverse health effects in humans, including re-
productive endocrine disorders and neurobehavioral problems
(Rochester, 2013). BPA is one of the best-studied endocrine dis-
rupting chemicals (EDCs), with more than 75 out of 91 published
studies showing associations between BPA exposure and ad-
verse human health effects as of May 2013 (Rochester, 2013).
The primary BPA mode of action is the activation of estrogen re-
ceptor (ER)-mediated transcription (Shioda et al., 2013).
Biomonitoring studies suggest that the urine from a majority of
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individuals in industrialized countries contain measurable BPA
and metabolites (Gerona et al., 2016). BPA has been detected in
breast milk (Nakao et al., 2015). The handling of a thermal re-
ceipt paper before eating French fries is sufficient to cause a
rapid increase of serum BPA levels within 30 min (Hormann
et al., 2014). A causal link between BPA and breast cancer re-
mains equivocal because epidemiological studies have reported
conflicting results (Rochester, 2013). Nonetheless, there is ample
evidence from laboratory rodent and non-human primate stud-
ies that prenatal exposure to BPA may increase the propensity
to develop breast cancer during adulthood (Mandrup et al., 2016;
Tharp et al., 2012). In these studies, low-doses of BPA have been
shown to affect mammary gland development by causing hy-
perplastic lesions in rats, which are parallel to early signs of
breast neoplasia in women (Mandrup et al., 2016). These find-
ings suggest that mammary tumors provoked by BPA may be
initiated in the womb. Due to mounting evidence of harm and
public pressure, BPA is being phased out by plastics manufac-
turers and is being replaced by other BP variants in “BPA-free”
products (Rochester and Bolden, 2015).
Bisphenol F (BPF), Bisphenol S (BPS), and Bisphenol AF (BPAF)
are among the main substitutes of BPA in polycarbonate plastics
and epoxy resins (Chen et al., 2016). They are commonly found in
baby feeding bottles, on thermal receipt papers, glues, dental
sealants, food packaging or personal care products. BPA alterna-
tives are detected in different categories of food items (Liao and
Kannan, 2013). There is a strong negative correlation between
the levels of BPA and BPS on thermal paper, whereby the papers
containing high quantities of BPS have low quantities of BPA,
suggesting that BPS has in part replaced BPA in this context (Liao
et al., 2012). Epidemiological data on the human body burden of
different BPA alternatives are very limited, but evidence suggests
that they are generally widespread. In an investigation of the
presence of BPS and BPF in human urine, these compounds were
found to be present in 78% and 55% of respective samples in the
United States (Zhou et al., 2014). Another investigation revealed
that although the average urinary concentration of BPA in 130 in-
dividuals from Saudi Arabia was 4.92 ng/ml, 7 other bisphenols
were found with the total bisphenol concentration reaching
19 ng/ml (Asimakopoulos et al., 2015), suggesting that BPA is only
one of many BP alternatives that are found in humans.
Some of these BPA replacements are structurally related to BPA
and have endocrine disrupting effects. Numerous studies have
suggested that BPS and BPF have potencies similar to that of BPA
resulting in endocrine disrupting effects such as uterine growth in
rodents (Rochester and Bolden, 2015). A number of in vitro studies
have looked at endocrine mode of action of some BPA alternatives
in nuclear hormone receptor interactions (Chen et al., 2016). The
range of EC50 values for estrogen activity (0.02 to >1000 mM) and
androgen activity (0.29 to>1000 mM) of 20 BP congeners (5 of which
are being tested here) indicates remarkable differences (Kitamura
et al., 2005). Another study showed that 5 BPA alternatives (3 stud-
ied here) exhibited potencies within the same range as BPA on ste-
roidogenesis, androgen receptor, aryl hydrocarbon receptor, and
retinoic acid receptor activity (Rosenmai et al., 2014). Some BPA al-
ternatives have also been tested in ER high-throughput screening
assays in the context of the US Environmental Protection Agency
(EPA) ToxCast program and shown in some cases to have
estrogen-like effects (Judson et al., 2015).
Perturbation of a cell’s gene expression profile by chemicals
results in specific signatures, allowing comparisons between
transcriptome alterations caused by drugs and diseases to pre-
dict therapeutic and off-target effects (Iorio et al., 2010). The clini-
cal utility of gene expression profiles is exemplified by studies
showing that transcriptome signatures may affect clinical
decision-making in breast cancer (Rhodes and Chinnaiyan, 2010).
Gene expression profiling has been shown to be a more powerful
predictor of breast cancer survival than standard systems based
on clinical and histologic criteria (van de Vijver et al., 2002).
Exposure of breast cancer cells to BPA presents a gene expression
profile of tumor aggressiveness associated with poor clinical out-
comes for breast cancer patients (Dairkee et al., 2008). While ER
activation drives two-thirds of breast cancer (Green and Carroll,
2007), there have been no studies aimed at elucidating transcrip-
tome alterations underlying estrogenic effects of a broad range of
BPA alternatives to which human populations are exposed. In or-
der to address this deficiency, we studied alterations in gene ex-
pression profiles of estrogen-dependent MCF-7 human breast
cancer cells caused by BPA and 6 alternatives (Figure 1) using
Affymetrix microarray and Illumina RNA sequencing platforms.
The transcriptome signatures obtained were compared with a
gene expression biomarker, which has been demonstrated to ac-
curately predict ER modulation, including by “very weak” ago-
nists (Ryan et al., 2016). We also used an E-screen assay (cell
proliferation in estrogen-responding cells) as well as an estrogen
response element (ERE)-luciferase reporter gene assay system.
Our results clearly demonstrate that all 6 BPA alternative com-
pounds are estrogenic. Alterations of MCF-7 transcriptome pro-
files caused by BPA alternatives bear the signature of ER
activation with three bisphenols (BPAF, BPB, BPZ) having more
estrogenic potency than BPA.
MATERIALS ANDMETHODS
Cell culture and treatments. All reagents and chemicals, unless oth-
erwise specified, were of analytical grade and purchased from
Sigma-Aldrich (UK). MCF-7, MDA-MB-231, and T47D human
breast cancer cell lines were a gift from Prof. Joy Burchell
(Research Oncology Department, King’s College London, United
Kingdom). The T47D-KBluc cells were purchased from the
American Type Culture Collection (ATCC, Teddington, United
Kingdom) and harbor a stably integrated copy of a luciferase
reporter gene under control of a promoter containing EREs. All
cells were grown at 37C (5% CO2) in 75 cm2 flasks (Corning,
Tewksbury, USA) in a maintenance medium composed of phenol
red-free DMEM (Life Technologies, Warrington, United Kingdom),
10% fetal bovine serum (FBS; GE Healthcare Life Sciences,
Buckinghamshire, United Kingdom), 2-mM glutamine (GE
Healthcare Life Sciences), and 10 mg/ml penicillin/streptomycin
(Life Technologies). Test substances were diluted in 100% ethanol
to prepare stock solutions. All treatments were prepared in a test
medium containing phenol red-free DMEM, 5% charcoal stripped
FBS (Life Technologies), 2-mM glutamine (GE Healthcare Life
Sciences), and 10 mg/ml penicillin/streptomycin (Life
Technologies) and contained no more than 0.1% ethanol. The sol-
vent control also contained 0.1% (v/v) absolute ethanol diluted in
test medium. Cells were detached from the flask substrate using
0.05% trypsin EDTA (Life Technologies) and counted using a hae-
mocytometer prior to seeding. After a 24-h recovery period in
DMEM maintenance medium, test substances were applied.
E-screen assay. The E-screen assay allows the determination of
estrogenic effects by determining ER-mediated cell proliferation
in hormone-responsive cells. This assay was performed as origi-
nally described (Soto et al., 1995), except that the bioassay was
terminated using an MTT assay, indirectly measuring cell num-
ber by testing the activity of mitochondrial succinate dehydro-
genase, in order to assess cell proliferation. The MTT assay has
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also been proven to be a reliable measure of toxicity (Mosmann,
1983). In brief, MCF-7, MDA-MB-231, and T47D cells were seeded
into 48-well plates (Dutscher Scientific, Brentwood, United
Kingdom) at a density of 20 000 cells per well in 250 ml mainte-
nance medium. Following a 24-h incubation to allow cell attach-
ment, medium was changed to include various concentrations
of treatment substances. A 6-day long incubation with the test
compounds allowed detection of variations in proliferative
rates, which were reflected by differences in cell number meas-
ured at the end of the incubation period. The test medium was
refreshed after 3 days. After another 3-day incubation, an MTT
assay was performed as follows. Cells were incubated with
250 ml of MTT solution (1 mg/ml) for 2 h and the test terminated
by lysing the cells with dimethyl sulfoxide (DMSO). As a meas-
ure of cell proliferation, the optical density of the cell lysate was
determined at 570 nm using the SPECTROstar Nano plate reader
(BMG Labtech, Ortenberg, Germany). The number of cells was
directly proportional to the intensity of the signal. The cell pro-
liferative effect was expressed as a percentage of the control,
untreated samples.
ERE-mediated luciferase reporter gene assay. The ERE-mediated
transcription of a luciferase reporter gene was determined in
the T47D-KBluc cells using the Steady-Glo luciferase assay sys-
tem following the manufacturer’s instructions (Promega,
Southampton, United Kingdom). The T47D-KBluc cells were
seeded in white 96 well plates (Greiner Bio-One, Germany) at a
density of 20 000 cells per well in 50 ml of maintenance medium
and allowed to attach overnight. An initial 24-h incubation was
performed in the absence of test substances to purge cells of
hormone residues in order to improve estrogen deprivation.
Test substances were added and plates were incubated for
another 24 h before the addition of 50 ml Steady-Glo luciferase
reagent. The plates were left to stand for 10 min in the dark at
room temperature to allow cell lysis and establishment of the
luciferase reaction. Luminescence was measured using the
Orion II microplate luminometer (Berthold Detection Systems,
Bad Wildbad, Germany). ER modulation was confirmed by
measuring the inhibitory effect of ICI 182,780 on the concentra-
tion of BPA resulting in a 20-fold increase in luciferase activity.
Microarray gene expression profiling. MCF-7 cells were seeded into
96-well plates with maintenance medium at a density of 20 000
cells per well. After 24 h of steroid hormone deprivation in
hormone-free medium, the cells were stimulated with test sub-
stances at a concentration corresponding to the E-Screen AC50 for
48 h in triplicate in 3 independent experiments. RNA extraction
was performed using the Agencourt RNAdvance Cell V2 kit
according to the manufacturer’s instructions (Beckman Coulter
Ltd, High Wycombe, United Kingdom). The samples were checked
for RNA quality using the Agilent 2100 Bioanalyzer (Agilent
Technologies LDA UK Limited, Stockport, United Kingdom) and
quantified using the Nanodrop ND-1000 Spectrophotometer
(Thermo Fisher Scientific, Wilmington, USA). The RNA integrity
number ranged from 7.9 to 10 (mean of 9.76 0.3) (Schroeder et al.,
2006). Subsequently, triplicate samples which passed quality
Figure 1. Molecular structures of BPA and bisphenol alternatives in comparison to the natural hormone 17b-estradiol.
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control (QC) criteria were pooled appropriately such that the final
input amount of each sample was 3 ng.
The gene expression profiles were determined using the
Affymetrix Human Transcriptome 2.0 Array as follows. Single
Primer Isothermal Amplified (SPIA) cDNA was generated using
the Ovation Pico WTA System V2 kit (Nugen, AC Leek, The
Netherlands) following the manufacturer’s instructions. In
addition, the SPIA cDNA was subjected to a QC check to assess
quality (Agilent 2100 Bioanalyzer) and quantity (Nanodrop ND-
1000 Spectrophotometer) in preparation for the next stage. The
SPIA cDNA was fragmented and biotin-labeled using the Encore
Biotin Module (Nugen) according to the manufacturer’s instruc-
tions. The fragmented and biotin-labeled cDNA was subjected
to a further round of QC checks to assess fragmentation size
(Agilent 2100 Bioanalyzer). Hybridization cocktails were pre-
pared from the fragmented labeled-cDNA according to Nugen’s
recommendations and hybridized to the microarrays at 45C
overnight. The arrays were washed and stained using the wash
protocol FS450_0001 recommended for Affymetrix Human
Transcriptome 2.0 Arrays on the GeneChip Fluidics 450 station.
Ultimately, the arrays were scanned using the Affymetrix
GeneChip Scanner. CEL files were QC assessed in the Expression
Console software package (Affymetrix) by using standard met-
rics and guidelines for the Affymetrix microarray system. Data
were imported and normalized together in Omics Explorer 3.0
(Qlucore, New York, NY, USA), using the Robust Multi-array
Average (RMA) sketch algorithm. These microarray data have
been submitted to Gene Omnibus and are accessible through
accession number GSE85350.
Gene expression profiling by RNA-Sequencing. RNA-Sequencing was
performed by applying Illumina sequencing by synthesis tech-
nology as follows. The amount of RNA for each library (100 ng)
was a pool made up of 33 ng of RNA from each of the replicate
wells for each sample. The preparation of the library was done
by NEBNext Ultra Directional RNA (New England Biolabs,
Hitchin, United Kingdom) following the manufacturer’s proto-
col. The amplified library was assessed using the Agilent 2100
Bioanalyzer for size and presence of adapter/primers/dimers—
sized at 400 bp (including 130 bp adapter). The rRNAs were
removed using the rRNA depletion module (New England
Biolabs) following the manufacturer’s protocol. Libraries were
pooled together and sequenced on a HiSeq2500 using a Rapid
Run v2 flowcell with on-board clustering in a 2  100 paired-end
(PE) configuration. BCL files were processed and deconvoluted
using standard techniques. The sequencing output FASTQ files
contained the sequences for each read and also a quality score.
We analyzed the quality scores and other metrics using
FASTQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/; last accessed May 23, 2017). Contamination from rRNA
was measured using an alignment script (http://genomespot.
blogspot.co.uk/2015/08/screen-for-rrna-contamination-in-rna.
html; last accessed May 23, 2017). Adapter sequences (standard
TruSeq LT adapter seq) were removed/trimmed using cutadapt
(Martin, 2011). Sequences were then aligned to the genome
(hg38 database) using the hierarchical indexing for spliced
alignment of transcripts program HISAT2 (Kim et al., 2015).
Binary Alignment/Map (BAM) files were imported to Qlucore
omics explorer, along with the Gene Transfer Format (GTF) file
for known genes in hg38 (downloaded from UCSC). Qlucore nor-
malizes data using a method similar to the trimmed mean of M-
values normalization method (TMM), which corrects for tran-
script length, applies a log transformation (Robinson and
Oshlack, 2010) and gives values similar to the quantification of
transcript levels in reads per kilobase of exon model per million
mapped reads (RPKM) (Robinson and Oshlack, 2010), but also
incorporates the TMM normalization factor for an improved
between-sample normalization.
A total of 376.6 million raw reads were obtained (25.165.4
million reads per sample). The average value of Q30, represent-
ing the probability of an incorrect base call 1 in 1000 times, was
above 96%. The GC content (%GC) of the reads was on average
49%. A total of 90.92%6 6.54% of the clean reads were mapped
onto the human reference genome hg38. Among them, an aver-
age of 71.01%65.82% and 18.25%63.79% reads align concord-
antly exactly one time and more than one time, respectively.
These RNA-Seq data have been submitted to Gene Omnibus
and are accessible through accession number GSE87701.
ToxCast data mining. Publically available data from the ToxCast
program was analyzed using the iCSS ToxCast Dashboard (http://
actor.epa.gov/dashboard/; last accessed May 23, 2017). In the
ToxCast program, out of 18 ER assays, 5 measured ERE-mediated
transcription and gave results comparable to those of our T47D-
Kluc assay. These assays measured ERa and ERb activities. One
assay was a single-readout fluorescent protein induction system
measuring interaction of ER with ERE at 2 time points by micro-
scopy technology (OT_ERa_EREGFP_0120 and _0048). Two other
assays were reporter gene assays measuring mRNA in HepG2 cells
(ATG_ERa_TRANS_up and ATG_ERE_CIS_up). The last 2 assays
measured reporter protein levels in HEK293T (Tox21_ERa_BLA_
Agonist_ratio) and BG-1 (Tox21_ERa_LUC_BG1_Agonist) cell lines.
One assay of protein complementation measures formation of ERa
dimers (OT_ER_ERaERa_0480 and _1440). Finally, NVS_NR_bER and
NVS_NR_hER are radioligand receptor binding assays. Not all assays
were performed on all bisphenols. For instance, BPAP was only
tested in Attagene assays (ATG_ERa_TRANS_up and ATG_ERE_CIS_
up). In this study, the AC50 value was used as a quantitative meas-
ure to reflect the potency of BP alternatives.
Comparison of the microarray and RNA-Seq data to the ER biomarker.
The Running Fisher test (a rank-based nonparametric analysis)
implemented within the NextBio database (Illumina, San Diego,
California) was used to compare gene lists derived from the
microarray and RNA-Seq data to the ER biomarker characterized
earlier (Ryan et al., 2016). The Running Fisher test is a normal-
ized ranking approach which enables comparability across data
from different studies, platforms, and analysis methods by
removing dependence on absolute values of fold-change, and
minimizing some of the effects of normalization methods used,
while accounting for the level of genome coverage by the differ-
ent platforms. The Running Fisher algorithm computes statisti-
cal significance of similarity between ranked fold-change
values of 2 gene lists using a Fisher’s exact test (Kupershmidt
et al., 2010). A P-value 1E4 was selected as our cutoff for sig-
nificance based on prior evaluation of the cutoff as predictive of
activation of ER (Ryan et al., 2016).
Statistical analysis. The concentration required to elicit a 50%
response (AC50) was determined using a nonlinear regression
fit using a sigmoid (5-parameters) equation calculated with
GraphPad software (GraphPad Software, Inc., La Jolla, California,
USA). For the transcriptome analysis, pair-wise comparisons of
each tested substance to the negative control were performed
using a t test controlling for batch effects in Omics Explorer 3.0
(Qlucore). Data used for the functional analysis were selected at
cut-off P-values <.05 with fold-change >1.2 to study the ER acti-
vation signature as previously described (Ryan et al., 2016). Gene
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and disease ontology were analyzed using the Thomson
Reuters MetaCore Analytical Suite version 6.28 recognizing net-
work objects (proteins, protein complexes or groups, peptides,
RNA species, compounds among others). The P-values are
determined by hypergeometric calculation and adjusted using a
Benjamini & Hochberg approach. All experiments were per-
formed 3 times in triplicate (n¼ 3).
RESULTS
E-Screen and ERE-Luciferase Reporter Gene Assays
We have studied the estrogenic activities of 7 bisphenols (BP)
found in foodstuffs and human biological fluids in three human
breast cancer cell lines. As an initial investigative step of estro-
genic potential, an E-Screen assay was performed using two hor-
mone dependent (MCF-7, T47D) and one hormone independent
(MDA-MB-231) human breast cancer cell lines (Figure 2A). The
positive control 17b-estradiol was very potent in inducing the
proliferation of MCF-7 cells (AC50¼ 8 pM). All BP derivatives were
also able to promote cell growth at concentrations 10 000–100 000
higher than 17b-estradiol (Figure 2A, top panel). BPAF was the
most potent BP (AC50¼ 0.03 mM) followed by BPZ (0.11 mM)>BPB
(0.24 mM)>BPA (0.36 mM)>BPAP (0.39 mM)>BPF (0.55 mM)>BPS
(1.33 mM). The same overall trend was observed with the T47-D
cell line (Figure 2A, middle panel), albeit to a lesser extent which
can be explained by the lower levels of ER expression in T47-D
cells (Pais and Degani, 2016). As expected no cell proliferative
effects were observed with the hormone independent, ER-
negative MDA-MB-231 cell line suggesting that proliferative
effects were mediated by ER (Figure 2a, bottom panel).
Since the observed BP-derivative induced proliferation of
MCF-7 and T47D cells (Figs. 2A and 2B) could be mediated by dif-
ferent receptors, estrogenic effects of BPA alternatives was
investigated employing a luciferase reporter gene assay allow-
ing measurement of ERE-mediated transcription. The results
(Figure 2B, upper panel) were very similar to those obtained
from the E-Screen assay: BPAF was the most potent bisphenol
(AC50¼ 0.08 mM) at stimulating ERE-luciferase reporter gene
expression followed by BPB (0.3 mM)>BPZ (0.4 mM)  BPA
(0.4 mM)>BPF (1 mM)  BPAP (1 mM)>BPS (1.5 mM) having estro-
genic effects in the same range as BPA. Moreover, the addition
of ICI 182,780 (100 nM) antagonized the activation of ER by estra-
diol and bisphenols confirming reporter gene expression via
this receptor (Figure 2C). However, estrogenic effects of some BP
derivatives, such as BPB and BPZ, were not completely antago-
nized by ICI addition, suggesting estrogenic activation mecha-
nisms independent of ER.
Figure 2. BPA alternatives can effectively substitute for estradiol in promoting growth through ERs of human breast cancer cells. (A) Proliferative effect of BPA and
bisphenol alternatives on mammary cells in an E-Screen bioassay. After 24 h of steroid hormone starvation cells were treated for 6 days with the test compounds.
Numbers of cells was measured by an MTT colorimetric assay. Results are expressed as proliferative effect percentage relative to the proliferation of cells under hor-
mone-free conditions. Data are the mean6SE of 3 independent experiments, with each performed in triplicate. (B) BPA alternatives stimulate ERE-mediated transcrip-
tion. After 24 h of steroid hormone starvation, T47D-Kluc cells were treated with the test compounds for 24 h. Cells were then lysed and subjected to a bioluminescence
luciferase reporter gene assay. (C) Luciferase assays of T47D-Kluc cells treated with BPA alternatives in the absence (black) or presence (red) of ICI 182,780, an ER antag-
onist. Results show that ICI 182,780 represses ERE-mediated transcription induced by BPA alternatives.
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ToxCast data mining (Table 1) confirms our results but also
reveals some discrepancies. BPF, BPZ, and BPB were classified
as inactive in the ToxCast gene reporter ERa_BLA_Agonist_ratio
assay, because they did not reach the response threshold, possi-
bly due to the lower sensitivity of this assay. For the 4 BPs that
were examined in the ER computational network model, BPA,
BPB, and BPAF were active and BPF was inactive (Judson et al.,
2015).
Transcriptome Profiling
MCF-7 cells treated for a period of 48 h with BPA, 6 BP alterna-
tives, or 17b-estradiol, were subjected to full transcriptome
profiling using the Affymetrix microarray platform. The length
of exposure (48 h) and the concentration of test agent were
selected based on data from previous studies showing that
these conditions produce robust gene expression changes
(Shioda et al., 2006). Supplementary File 1 shows the statistical
significance of differential transcript cluster expression with
respective fold-changes by volcano plots. The visual representa-
tion of the variance structure obtained by a principal compo-
nent analysis indicates that samples treated with BPA and BP
alternatives separates from the control samples (Figure 3A) and
cluster along samples treated with 17b-estradiol. This result is
corroborated by the heatmap representation of the 1000 most
differentially expressed genes according to a one-way ANOVA
(Figure 3B). Surprisingly, samples treated with BPS and the 2
highest concentrations of 17b-estradiol clustered together, dis-
tantly of the negative control (Figure 3B). They were also segre-
gated from other samples presenting a mixed pattern (Figure
3B). The set of genes altered by treatment with BPA and BP alter-
natives (Supplementary File 2) were highly enriched in genes
involved in the regulation of the cell cycle (Figure 4A), as well as
in genes regulated by steroid hormones (Figure 4B). Samples
treated with BPS and the 2 highest concentrations of 17b-estra-
diol were the most enriched for cell cycle annotation, confirm-
ing their discordant pattern (Figure 3B). In addition, an
enrichment analysis of MeSH terms reveals that exposure to
both BPA or the 6 BP alternatives result in changes in the
expression of genes involved in the etiology of breast cancer
(Figure 4C). Genes having the highest fold-changes were similar
and indicative of a hormone-induced proliferative effect (Table
2). The gene encoding the progesterone receptor (PGR) consis-
tently exhibited the highest fold-change after stimulation with
BPA or all the BP alternatives. ER binding motifs were overrepre-
sented in the promoter of the differentially expressed genes
(DEGs). There were 4.8–6.4 more ER binding sequences (EREs) in
the promoters of the DEGs than what would be expected by
chance (Figure 4D).
Statistical values derived from gene ontology analysis can
have limited reliability due to the background set including only
the genes that are likely to be expressed in the experiment
(Tipney and Hunter 2010). Genes disturbed by chance have a
higher probability to be associated with endocrine ontologies in
an endocrine sensitive tissue such as the breast. This could
result in an increased false positive rate. In order to circumvent
this problem, we applied a biomarker approach to predict ER
modulation. The gene expression biomarker consists of 46
genes which exhibit consistent expression patterns after expo-
sure to 7 ER agonists and 3 ER antagonists determined using
MCF-7 microarray data derived from the CMAP 2.0 dataset
(Ryan et al., 2016). This gene expression biomarker has a bal-
anced accuracy for prediction of ER activation of 94%. Gene
expression profiles from the cells treated with BPA and BP alter-
natives were compared to the ER biomarker using the RunningT
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Fisher algorithm as previously described (Ryan et al., 2016). The
cut-off value for statistical significance was P-value .0001 after
a Benjamini-Hochberg correction of a¼ 0.001. All transcriptome
profile alterations resulting from exposure to BPA and all 6 BP
alternatives (Figure 4E) achieved statistical significance and
exhibited a pattern highly similar to that of the biomarker
(Figure 4F).
We finally investigated differences in gene expression pat-
terns provoked by BPA alternatives in MCF-7 cells. This was
done by identifying pathways, which were disturbed by BPA
alternatives but not by BPA itself, using the Metacore pathway
maps tool. The list of all pathways altered by the different treat-
ments is shown in Supplementary File 3. BPS had the most dis-
cordant pattern with 33 pathways statistically significantly
altered, which were not disturbed by BPA. The high concentra-
tion necessary to activate ER could also possibly induce toxic
effects as indicated by the disturbance of apoptotic pathways
(FDR corrected P-value¼ 2.5e2). This Metacore analysis also
suggested that BPAF is a modulator of the glucocorticoid recep-
tor (GR) (FDR corrected P-value¼ 1.9e4). A synergistic activa-
tion of GR and ER could possibly explain the strong cell
proliferation stimulatory effect of BPAF starting from 10 nM
(Figure 2A), a concentration at which this compound does not
appear to be estrogenic (Figure 2B).
In order to confirm estrogenic effects provoked by BPA and
BP alternatives, RNA extracted from MCF-7 cells treated with
BPAF (0.08 mM), BPA (0.36 mM), and estradiol (1 nM) were sub-
jected to total transcriptome RNA sequencing (RNA-Seq) analy-
sis using the Illumina HiSeq 2500 system. This also allowed us
to compare the sensitivity of RNA-Seq and microarrays to deter-
mine estrogenic effects. We have performed pairwise compari-
sons to determine the list of DEGs following the same criteria
used for the microarray analysis. Only 12%-21% of the DEGs
identified by RNA-Seq were also found to be altered on the
microarrays (Figure 5B). The gene expression fold changes
common to both the microarray and the RNA-Seq analysis were
well correlated (Figure 5A) for 17b-estradiol (Pearson r¼ 0.81),
BPA (r¼ 0.86), and BPAF (r¼ 0.81). Overall, the RNA-Seq method
was more sensitive and identified 2-3 times more significantly
altered genes compared with the microarray method (Figure
5B). A total of 5091, 2930, and 3093 genes were significantly
altered by estradiol, BPA, and BPAF, respectively. Genes com-
monly found altered after the application of both transcriptome
profiling methods generally had a higher fold change by the
RNA-Seq platform (Supplementary File 4). The ontology analysis
based on RNA-Seq data gave similar results to our previous cal-
culations based on the microarray data and confirms estrogenic
effects of BPA and BPAF (Figure 5C). Although more DEGs related
to cell cycle function were found by RNA seq than by microar-
ray, the log10 P-value for BPA was lower because the total
number of DEGs found by RNA seq was higher than by microar-
ray. We similarly applied the ER gene expression biomarker to
detect ER agonists after analysis with the Illumina sequencing
platform (Figs. 5D and 5E). The RNA-Seq platform gave results
similar to that of Affymetrix microarrays confirming estrogenic
effects of the BPA alternatives.
DISCUSSION
Human populations are exposed to a wide range of BPA alterna-
tives. Presented here is the first comprehensive, side-by-side
comparison of the estrogenic effects of BPA and 6 BP variants
(BPZ, BPAF, BPAP, BPB, BPF, BPS) found in foodstuffs and human
fluids using both cell proliferation and gene expression profile
assays. Our study revealed that the 6 bisphenols introduced in
“BPA-free” plastics displayed estrogenic effects with BPAF, BPB,
and BPZ being more potent than BPA in our experimental sys-
tem. The comparison of transcriptome profiles revealed a signa-
ture demonstrating that these effects were mediated via the ER
Figure 3. Variation in the transcriptome profiles of MCF-7 cells exposed to BPA alternatives and 17b-estradiol. (A) PCA analysis of gene expression profiles showed a
clear separation between the negative control and the BPA alternatives. The different colors indicate different treatments. (B) Expression of the 1000 genes presenting
the most pronounced variations between the different samples was evaluated according to a one-way ANOVA. Hierarchical clustering revealed different patterns in
gene expression between the BPA alternatives and 17b-estradiol-treated cells.
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(Figs. 4A–F). Although data on plasma concentrations of BPA
alternatives are scarce (Chen et al., 2016), the potencies reported
in this study are likely to be much higher than concentrations
found in most cases of human environmental exposures. Our
results suggest the need to conduct studies to examine possible
pathological effects in laboratory animals at concentrations rel-
evant for human exposures. In addition, combined effects of
these bisphenols should be explored in further studies to deter-
mine the relevance of these estrogenic effects in terms of
human health-risk assessment. In particular, our results pro-
vide a basis for investigating the relevance of human exposure
to BPA alternatives in hormone-dependent breast cancer pro-
gression. The structure of BPA alternatives (Figure 1) provides
insights into the possible mechanisms of action toward ER. BPA
Figure 4. Alteration of MCF-7 transcriptome profiles caused by BPA alternatives bear the signature of ER activation. Transcriptome analysis of MCF-7 cells treated with
BPA and alternative bisphenols reflect cell cycle changes (A), response to hormone (B), as well as an association to breast cancer (C). The P-values are determined by
hypergeometric calculation and adjusted using a Benjamini and Hochberg approach. Ratios show the total number of network objects belonging to each term in com-
parison to those disturbed by the treatments. The total of network objects (ie, all DEG) recognized by Metacore are indicated in parentheses (D). Overrepresentation of
ER binding motifs in the promoters of the differentially expressed genes. The analysis conducted with the transcription factor analysis tool of Metacore. A total of 1262
ER binding sites is found in the 42 909 protein-based objects in the Metacore background list. A, number of targets in the activated dataset regulated by ESR1; E,
expected mean of hypergeometric distribution; P-value calculated using hypergeometric distribution. (E) A gene expression biomarker confirms that BPA and bisphenol
alternatives are ER agonists. Lists of statistically significant genes from MCF-7 cells treated with BPA and bisphenol alternatives or the natural hormone 17b-estradiol
were examined against an ER gene expression biomarker signature consisting of 46 genes. The heat map shows the expression of genes in the biomarker after expo-
sure to the indicated compound. Fold-change values for the ER biomarker are the average across 7 agonist treatments. (F) Bar plots showing the significance of the cor-
relation by their log10 P-values. Classification of activation or suppression required P< .0001. The number of genes overlapping the ER biomarker is indicated at the
top of each bar.
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binding to ER is mainly driven by van der Waals’ forces and
hydrogen bond interactions (Li et al., 2015). BPA and 17b-estradiol
bind in a similar manner, with 2 phenol rings pointing to the 2
ends of the ER hydrophobic pocket. Differences in estrogenic activ-
ities between the different BPA alternatives may be due to the dif-
ferent groups present at the bridge between the 2 phenol rings.
Their hydrophobicity is driving their affinity, since the matching
of the group carried by the methylene bridge is known to deter-
mine binding affinity toward the hydrophobic surface of the ER
binding site (Endo et al., 2005). Such a mechanism of ER interaction
is supported by the hydrophobicity ranking of bisphenols (logP
values BPZ>BPAF>BPAP>BPB>BPA>BPF>BPS), which closely
corresponds to their AC50 toxicity score.
It is important to note that in some cases EDCs can elicit a
non-monotonic response that significantly deviates from the
usual sigmoidal curve (Vandenberg et al., 2012). In another tran-
scriptomics study in which MCF-7 cells were exposed to varying
concentrations of BPA, a weak gene activation peak at a very
low concentration range (0.1 nM) was observed in addition to
the main peak of gene activation (Shioda et al., 2013). In
addition, an investigation of the combinatorial effects of bisphe-
nols would reflect real-world exposure conditions even if estro-
genic effects of chemical mixtures in vitro are predicted by the
use of concentration addition models (Evans et al., 2012).
Our data allow a direct comparison of the sensitivity of RNA-
Seq and microarray hybridization in the determination of the
transcriptome signature of ERa activation. Overall, the applica-
tion of RNA-Seq resulted in the detection of more statistically
significant alterations in gene expression than the microarray
method. These genes generally had a higher fold change leading
to P-values associated with gene expression biomarkers being
lower. Overall, RNA sequencing appears to be more sensitive
than microarray analysis. This was also the conclusion of stud-
ies performed in other cell lines (Perkins et al., 2014), mesenchy-
mal stem cells (Li et al., 2016), and rat tissues (Perkins et al.,
2014). In a study of 498 primary neuroblastomas, RNA-Seq out-
performed microarrays in determining the transcriptomic
characteristics of these cancers, while RNA-Seq and microarray
performed similarly in clinical endpoint prediction (Zhang et al.,
2015). Both technologies are suitable to detect estrogenic effects
of BPA alternatives using the gene expression biomarker of ERa
activation. Although the genes weakly expressed were differen-
tially detected by the two platforms, the biomarker signatures
were comparable. However, it is perhaps noteworthy that the
microarray processing and analysis pipelines are better stand-
ardized and could thus be more reliable in comparing experi-
ments performed by different laboratories. Further intra- and
inter-experimental comparisons would be necessary to con-
clude which method is the most sensitive and reliable to deter-
mine transcriptome signatures.
The mechanisms of action resulting in toxic effects from
BPA at low levels of exposure have long remained elusive due to
its relatively low affinity for ER. However, BPA is very potent at
inducing rapid non-genomic responses from membrane surface
receptors (Wozniak et al., 2005). For example, BPA administra-
tion inhibited meiotic maturation of Zebrafish oocytes through
a G protein-coupled ER-dependent epidermal growth factor
receptor pathway (Fitzgerald et al., 2015). BPA can also induce
adipogenesis through other receptors such as peroxisome
proliferator-activated receptor gamma (PPARc) (Ahmed and
Atlas 2016). Surprisingly, this latest study provided evidence
that BPS is a more potent adipogen than BPA in inducing 3T3-L1
adipocyte differentiation and lipid accumulation. Overall,
effects of BPA alternatives on G protein-coupled ERs have poorly
been investigated. Recent studies have revealed that less
studied endocrine-related systems such as glucocorticoid,
PPAR, monoamine, noradrenaline, and serotonin pathways
could also be targets of endocrine disruption (Filer et al., 2014).
Our transcriptome profiling of MCF-7 cells exposed to BPAF
revealed that it could be a modulator of the GR. This could
explain the potent cell proliferation stimulatory effects of BPAF
starting from 10 nM (Figure 2A). However, targeted studies of GR
modulation are needed to allow a firm conclusion on such a
BPAF-ER interaction.
Table 2. List of the 5 Most Up- or Down-Regulated Genes After Treatment With BPA, BPAF or Estradiol (E2)
E2 (10 pM) E2 (100 pM) E2 (1 nM) BPA BPAF
ALDH1A3 0.4 ALDH1A3 0.2 ALDH1A3 0.2 SEMA5A 0.3 ALDH1A3 0.3
SEMA5A 0.4 PRICKLE2-AS3 0.2 PSCA 0.2 ALDH1A3 0.3 PSCA 0.4
PPARG 0.5 SEMA5A 0.3 TFPI 0.2 PSCA 0.3 RP11-706C16.7 0.4
PSCA 0.5 PSCA 0.3 PRICKLE2-AS3 0.2 PRICKLE2-AS3 0.3 SEMA5A 0.4
IGFBPL1 0.5 EPAS1 0.3 EPAS1 0.3 GABBR2 0.3 EPAS1 0.4
AC005534.8 2.6 MYBL1 5.5 AC106875.1 6.4 AC106875.1 3.3 AGR3 3.2
MYB 3.0 AC106875.1 6.3 MYBL1 6.5 MYB 3.7 MYB-AS1 3.4
AC106875.1 3.2 GREB1 7.1 GREB1 7.1 GREB1 3.8 MGP 3.5
GREB1 3.7 PGR 10.0 PGR 9.2 MGP 4.2 MYB 4.1
PGR 4.6 MGP 12.4 MGP 15.0 PGR 6.2 PGR 5.7
BPB BPF BPS BPZ BPAP
ALDH1A3 0.3 ALDH1A3 0.3 ALDH1A3 0.2 ALDH1A3 0.3 ALDH1A3 0.3
GABBR2 0.3 SEMA5A 0.3 PSCA 0.3 TFPI 0.3 SEMA5A 0.4
PSCA 0.3 EPAS1 0.4 SEMA5A 0.3 GABBR2 0.3 GABBR2 0.4
PRICKLE2-AS3 0.4 PSCA 0.4 TFPI 0.3 PSCA 0.4 TFPI 0.4
EPAS1 0.4 HCAR3 0.4 PRICKLE2-AS3 0.3 EPAS1 0.4 EPAS1 0.4
AGR3 3.3 MYB 3.9 AC106875.1 5.4 STC1 2.8 STC1 3.1
GREB1 3.8 MYB-AS1 4.4 MYB 5.7 ASCL1 2.9 AL121578.2 3.1
MYB 4.1 GREB1 4.5 GREB1 6.0 AGR3 3.3 MYB 3.8
MGP 4.4 MGP 5.0 MGP 7.8 MYB-AS1 3.4 AGR3 3.8
PGR 6.8 PGR 6.5 PGR 9.5 PGR 5.8 PGR 5.8
The transcriptome profiling was performed using the Affymetrix microarray platform.
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In adult humans, BPA is rapidly metabolized by the liver,
with elimination virtually complete within 24 h of exposure,
although chronic exposures could result in accumulation if BPA
distributes within tissues that slowly release BPA (Stahlhut
et al., 2009). In an investigation of concentrations of BPA metab-
olites in the urine of 112 pregnant women (ethnically and
racially diverse), total BPA consisted of 71% BPA glucuronide,
15% BPA sulfate, and 14% unconjugated BPA (Gerona et al.,
2016). These metabolites are believed to be biologically inactive
because they are not thought to be ER agonists. However, this
does not preclude effects on other receptor systems or the
creation of an equilibrium between the metabolite and the
parent if the metabolite is long-lived. For instance, a recent
study showed that BPA glucuronide can induce lipid accumula-
tion and differentiation of pre-adipocytes (Boucher et al., 2015).
Metabolites of the main BPA alternatives have not been rou-
tinely measured in human biomonitoring studies, which may
greatly underestimate real world exposures. Moreover, BPA
metabolites may be deconjugated by b-glucuronidase, which is
particularly active in the placenta and fetal liver resulting in
increased fetal exposure (Ginsberg and Rice 2009). Although it is
known that UGT2B15, the UDP-glucuronosyltransferase most
Figure 5. Comparison of RNA-Seq and microarray platforms in determining endocrine disrupting effects of BPA and bisphenol alternatives. RNA extracted from MCF-7
cells was subjected to a full transcriptome profiling using the Illumina RNA sequencing or the microarray technology under similar conditions. (A) Pearson correlation
coefficients between the RNA-Seq and microarray data. The fold changes in gene function having an altered expression by the two methods are presented. (B) Venn
diagrams showing the number of genes uniquely or commonly disturbed. (C) Gene ontology analysis of terms associated with MCF-7 hormone induced proliferation in
the transcriptome profiles obtained by RNA-Seq or microarray analysis. Ratios are showing the total number of network objects belonging to each term in comparison
to those disturbed by the treatments. The total of network objects (ie, all DEG) recognized by Metacore are indicated in parentheses. (D) Heat map of genes whose
expression was statistically significantly altered examined against an ER gene expression biomarker. (E) Bar plots showing the significance of the correlation by their
log10 P-values.
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effective at conjugating BPA, is expressed at low levels in the
fetal liver, it increases postnatally to maximum values between
3 and 15 weeks after birth. In contrast, SULT1A1, the sulfotrans-
ferase most effective in sulfating BPA, is expressed at levels in
the fetal liver equivalent to the adult. Thus, it is also important
to consider the efficiency of the fetus at conjugating BPA with
sulfate (Divakaran et al., 2014; Duanmu et al., 2006). Previous
studies showed that UGT2B15 is active in MCF-7 breast cancer
cells (Harrington et al., 2006). Further studies comparing estro-
genic effects of BPA alternatives in cell lines devoid of UDP-
glucuronosyltransferases could also provide interesting insights
into the pathways of possible toxicity of this compound.
Even though disruption of ER function is one of the most
investigated endocrine-related targets in the ToxCast data (18
assays) (Judson et al., 2015), our analysis of the high-throughput
system (HTS) employed has revealed a lack of concordance
between our results and the HTS ToxCast assays, with some of
these ToxCast assays failing to detect estrogenic effects (Table
1). This was especially the case for BPF which was found nega-
tive in 9 out of the 11 assays scrutinized. The 2 systems of anal-
ysis detecting the estrogenic capability of BPF were the
Attagene assays. BPF was found to be less potent in these assays
than in this study (Table 1). Our results are in agreement with
previously published estrogenic effects of BPF reporting an EC50
of 0.82 mM in an ER luciferase assay (Rosenmai et al., 2014). BPAP
on the other hand was found to be more potent in the ToxCast
assays, although the difference within the 2 current assays was
minimal and could be explained by different grades of chemical
purity. Another reason for these differences could be the differ-
ent sensitivities of HTS assays. These are frequently based on
heterologous expression of reporter genes in non-hormone-
responsive cell lines that possibly do not possess all the co-
factors necessary to transduce the hormone signal, thus result-
ing in a decreased sensitivity to detect relevant signals.
The US EPA has proposed the Endocrine Disruptor Screening
Program Tier 1 assays with the goal of reducing the cost and
time of toxicity testing, as well as animal use (US EPA, 2015).
The US EPA will consider certain in vitro high throughput assays
and computational modeling data as alternatives for detecting
and measuring ER agonist and antagonist bioactivity by three
current EDSP Tier 1 screening battery assays (that is, the ER
binding in vitro assay, the ER transcriptional activation in vitro
assay, and the in vivo uterotrophic assay) (US EPA, 2015).
Integrating gene expression profiling into the proposed HTS
framework might add value to targeted in vitro testing, because
multiple targets and pathways could be evaluated simultane-
ously (Ryan et al., 2016). Transcriptome profiles resulting from
exposure to a given chemical could be correlated to signatures
of a wide range of chemicals using the Library of Integrated
Network-based Cellular Signatures (LINCS) database, which
contains signatures from around 4000 chemicals screened in
approximately 17 cell lines (http://www.lincsproject.org; last
accessed May 23, 2017) or to the 1300 chemicals that were
examined in multiple cell lines as part of the Connectivity Map
project (Lamb et al., 2006).
CONCLUSION
We have detected estrogenic effects of BPA alternatives by the
application of a gene expression biomarker of ERa activation,
whose results are corroborated by functional cellular assays.
Our comparison of microarray and RNA-Seq technologies
showed that both platforms are suitable for the use of this ERa
gene expression biomarker. Recently, the plastics
manufacturing industry have turned to alternative bisphenols
to produce their “BPA-free” products, often with little toxicology
testing. Our data show that some of these BPA alternatives are
more potent ER activators than BPA, suggesting that alternative
testing strategies could provide valuable information to support
decisions related to chemical substitutions.
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online.
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